Cargando…

Medical treatment of early stage and rare histological variants of epithelial ovarian cancer

Epithelial ovarian cancer is often considered a single pathological entity, but increasing evidence suggests that it is rather a group of different neoplasms, each with unique pathological characteristics, molecular features, and clinical behaviours. This heterogeneity accounts for the different sen...

Descripción completa

Detalles Bibliográficos
Autores principales: Cont, Nicoletta Tomasi, Ferrero, Annamaria, Peccatori, Fedro Alessandro, D’Alonzo, Marta, Codacci-Pisanelli, Giovanni, Colombo, Nicoletta, Biglia, Nicoletta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631577/
https://www.ncbi.nlm.nih.gov/pubmed/26557882
http://dx.doi.org/10.3332/ecancer.2015.584
_version_ 1782398884048273408
author Cont, Nicoletta Tomasi
Ferrero, Annamaria
Peccatori, Fedro Alessandro
D’Alonzo, Marta
Codacci-Pisanelli, Giovanni
Colombo, Nicoletta
Biglia, Nicoletta
author_facet Cont, Nicoletta Tomasi
Ferrero, Annamaria
Peccatori, Fedro Alessandro
D’Alonzo, Marta
Codacci-Pisanelli, Giovanni
Colombo, Nicoletta
Biglia, Nicoletta
author_sort Cont, Nicoletta Tomasi
collection PubMed
description Epithelial ovarian cancer is often considered a single pathological entity, but increasing evidence suggests that it is rather a group of different neoplasms, each with unique pathological characteristics, molecular features, and clinical behaviours. This heterogeneity accounts for the different sensitivity to antineoplastic drugs and makes the treatment of ovarian tumours a challenge. For early-stage disease, as well as for heavily pre-treated patients with recurrent ovarian cancer, the benefit of chemotherapy remains uncertain. Clear-cell, mucinous, low-grade serous, and endometrioid carcinomas show different molecular characteristics, which require different therapeutic approaches. In the era of personalised cancer medicine, understanding the pathogenesis and the genetic background of each subtype of epithelial ovarian tumour may lead to a tailored therapy, maximising the benefits of specific treatments and possibly reducing the side effects. Furthermore, personal factors, such as the patient’s performance status, should be taken into account in the management of ovarian cancer, with the aim of safeguarding the patients’ quality of life.
format Online
Article
Text
id pubmed-4631577
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Cancer Intelligence
record_format MEDLINE/PubMed
spelling pubmed-46315772015-11-10 Medical treatment of early stage and rare histological variants of epithelial ovarian cancer Cont, Nicoletta Tomasi Ferrero, Annamaria Peccatori, Fedro Alessandro D’Alonzo, Marta Codacci-Pisanelli, Giovanni Colombo, Nicoletta Biglia, Nicoletta Ecancermedicalscience Review Epithelial ovarian cancer is often considered a single pathological entity, but increasing evidence suggests that it is rather a group of different neoplasms, each with unique pathological characteristics, molecular features, and clinical behaviours. This heterogeneity accounts for the different sensitivity to antineoplastic drugs and makes the treatment of ovarian tumours a challenge. For early-stage disease, as well as for heavily pre-treated patients with recurrent ovarian cancer, the benefit of chemotherapy remains uncertain. Clear-cell, mucinous, low-grade serous, and endometrioid carcinomas show different molecular characteristics, which require different therapeutic approaches. In the era of personalised cancer medicine, understanding the pathogenesis and the genetic background of each subtype of epithelial ovarian tumour may lead to a tailored therapy, maximising the benefits of specific treatments and possibly reducing the side effects. Furthermore, personal factors, such as the patient’s performance status, should be taken into account in the management of ovarian cancer, with the aim of safeguarding the patients’ quality of life. Cancer Intelligence 2015-10-22 /pmc/articles/PMC4631577/ /pubmed/26557882 http://dx.doi.org/10.3332/ecancer.2015.584 Text en © the authors; licensee ecancermedicalscience. http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Cont, Nicoletta Tomasi
Ferrero, Annamaria
Peccatori, Fedro Alessandro
D’Alonzo, Marta
Codacci-Pisanelli, Giovanni
Colombo, Nicoletta
Biglia, Nicoletta
Medical treatment of early stage and rare histological variants of epithelial ovarian cancer
title Medical treatment of early stage and rare histological variants of epithelial ovarian cancer
title_full Medical treatment of early stage and rare histological variants of epithelial ovarian cancer
title_fullStr Medical treatment of early stage and rare histological variants of epithelial ovarian cancer
title_full_unstemmed Medical treatment of early stage and rare histological variants of epithelial ovarian cancer
title_short Medical treatment of early stage and rare histological variants of epithelial ovarian cancer
title_sort medical treatment of early stage and rare histological variants of epithelial ovarian cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631577/
https://www.ncbi.nlm.nih.gov/pubmed/26557882
http://dx.doi.org/10.3332/ecancer.2015.584
work_keys_str_mv AT contnicolettatomasi medicaltreatmentofearlystageandrarehistologicalvariantsofepithelialovariancancer
AT ferreroannamaria medicaltreatmentofearlystageandrarehistologicalvariantsofepithelialovariancancer
AT peccatorifedroalessandro medicaltreatmentofearlystageandrarehistologicalvariantsofepithelialovariancancer
AT dalonzomarta medicaltreatmentofearlystageandrarehistologicalvariantsofepithelialovariancancer
AT codaccipisanelligiovanni medicaltreatmentofearlystageandrarehistologicalvariantsofepithelialovariancancer
AT colombonicoletta medicaltreatmentofearlystageandrarehistologicalvariantsofepithelialovariancancer
AT biglianicoletta medicaltreatmentofearlystageandrarehistologicalvariantsofepithelialovariancancer